Dana Farber Cancer Institute shared a post on Linkedin:
“Mohammad Rashidian has been named a 2026 Cancer Research Institute (CRI) Lloyd J. Old STAR for his discovery of a signaling hub that unlocks durable, exhaustion-resistant anti-tumor T-cell immunity. The award honors bold scientific innovation by providing each awardee with $1.25 million in flexible funding over five years for high-risk, high-reward research in cancer immunotherapy.
Please join us in congratulating him on this recognition.
Read further.”
Other articles about Dana-Farber Cancer Institute on OncoDaily.